Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.7K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.9K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.9K
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regenerative macrophages enhance stem cell-derived β cell function and engraftment.

Science advances·2026
Same author

Engineering human T cells with antigen receptors for immune regulation in autoimmune disease and transplantation.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows.

Cell reports methods·2026
Same author

Human and mouse regenerative macrophages enhance beta cell survival, function, and proliferation.

Islets·2026
Same author

Beta Integrin Expression Defines Functionally Distinct CD4<sup>+</sup> T-Cell Subsets That Are Altered in Ulcerative Colitis.

Gastro hep advances·2026
Same author

Chronic graft-versus-host disease suppressing CD56<sup>bright</sup>Perforin<sup>neg</sup> regulatory-like NK cells inhibit CD4<sup>+</sup> T cells via PD-1, LAG-3, and TRAIL.

Cytotherapy·2026

Related Experiment Video

Updated: May 5, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

15.0K

Graft-versus-host disease: suppression by statins.

Raewyn Broady1, Megan K Levings

  • 1Department of Medicine, University of British Columbia and Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.

Nature Medicine
|November 8, 2008
PubMed
Summary

Statins may help control graft-versus-host disease after stem cell transplants. The Edmonton protocol shows promise for type 1 diabetes but requires further development for long-term success.

More Related Videos

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
09:50

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice

Published on: February 11, 2019

8.8K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.3K

Related Experiment Videos

Last Updated: May 5, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

15.0K
Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
09:50

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice

Published on: February 11, 2019

8.8K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.3K

Area of Science:

  • Transplantation biology
  • Immunology
  • Endocrinology

Background:

  • Hematopoietic stem cell transplantation (HSCT) faces challenges in managing graft-versus-host disease (GVHD).
  • Organ transplantation requires overcoming host rejection of donor organs.
  • The Edmonton protocol offers short-term glucose control for type 1 diabetes but lacks long-term efficacy.

Purpose of the Study:

  • To explore potential therapeutic strategies for mitigating GVHD after HSCT.
  • To review the efficacy and limitations of the Edmonton protocol for type 1 diabetes management.
  • To discuss advancements in transplantation biology for improving patient outcomes.

Main Methods:

  • Review of existing studies on statin use in GVHD.
  • Analysis of the Edmonton protocol's mechanisms and clinical outcomes.
  • Synthesis of current research in transplantation immunology and endocrinology.

Main Results:

  • Emerging evidence suggests statins may possess immunomodulatory properties beneficial for controlling GVHD.
  • The Edmonton protocol successfully restores insulin production but faces challenges with graft survival and long-term glycemic control.
  • Significant hurdles remain in both preventing immune-mediated complications in HSCT and achieving sustained therapeutic effects in islet transplantation.

Conclusions:

  • Statins represent a potential avenue for managing GVHD, warranting further investigation.
  • The Edmonton protocol provides a foundation for islet transplantation but requires significant improvements for widespread, long-term application in type 1 diabetes.
  • Addressing immune responses is critical for advancing both HSCT and solid organ/islet transplantation.